Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies

CNS Neuroscience and Therapeutics

Volumn 22, Issue 1, 2016, Pages 25-37

  Rolland, Benjamin ^a,b   Paille, François ^a,c   Gillet, Claudine ^a,d   Rigaud, Alain ^a,e,f   Moirand, Romain ^a,g,h   Dano, Corine ^a,i   Dematteis, Maurice ^a,j   Mann, Karl ^k,l   Aubin, Henri Jean ^a,l,m  

^a Société Française d Alcoologie   (France)

^b UNIV LILLE   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d Hospital Villemin   (France)

^e Châlons en Champagne et Reims   (France)

^f ANPAA Association Nationale de Prévention en Alcoologie et Addictologie   (France)

^g RENNES UNIVERSITY HOSPITAL   (France)

^h INSERM   (France)

ⁱ ANGERS UNIVERSITY HOSPITAL   (France)

^j UNIV GRENOBLE ALPES   (France)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l HOSPITAL CLÍNIC   (Spain)

^m HÔPITAL PAUL BROUSSE   (France)

more..

Author keywords

Addiction medicine; Alcohol; Alcoholism; France; Guidelines; Pharmacotherapy; Primary care

Indexed keywords

ACAMPROSATE; BENZODIAZEPINE DERIVATIVE; DISULFIRAM; NALMEFENE; NALTREXONE; THIAMINE; DRUGS USED IN THE TREATMENT OF ADDICTION;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; COMORBIDITY; DELIRIUM TREMENS; DETOXIFICATION; DRUG MONITORING; HEALTH PROGRAM; HUMAN; MEDICAL HISTORY; MEDICAL PRACTICE; MEDICAL SOCIETY; NUTRITIONAL STATUS; PHARMACEUTICAL CARE; SEIZURE; SUBSTANCE ABUSE; TREATMENT DURATION; FEMALE; FRANCE; MALE; OFF LABEL DRUG USE; PREGNANCY; PREGNANCY COMPLICATIONS; PROCEDURES; SECONDARY PREVENTION;

ALCOHOL DETERRENTS; ALCOHOLISM; FEMALE; FRANCE; HUMANS; MALE; OFF-LABEL USE; PREGNANCY; PREGNANCY COMPLICATIONS; SECONDARY PREVENTION; SOCIETIES, MEDICAL;

EID: 84954445443     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12489     Document Type: Article

References (93)

1. Laramee P, Kusel J, Leonard S, Aubin HJ, François C, Daeppen JB. The economic burden of alcohol dependence in Europe. Alcohol Alcohol 2013;48:259-269.
2. European Medicines Agency. Guideline on the development of medicinal products for the treatment of alcohol dependence. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/03/WC500074898.pdf (Accessed 01/09/15).
3. Marlatt GA, Witkiewitz K. Harm reduction approaches to alcohol use: Health promotion, prevention, and treatment. Addict Behav 2002;27:867-886.
4. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Organ 2004;82:858-866.
5. Aubin HJ, Daeppen JB. Emerging pharmacotherapies for alcohol dependence: A systematic review focusing on reduction in consumption. Drug Alcohol Depend 2013;133:15-29.
6. Haute Autorité de Santé, Société Française d'Alcoologie. Conférence de consensus 7 et 8 mars 2001: modalités de l'accompagnement du sujet alcoolodépendant après un sevrage. http://www.has-sante.fr/portail/upload/docs/application/pdf/alcool2.pdf (Accessed 01/09/15).
7. Haute Autorité de Santé, Société Française d'Alcoologie. Conférence de consensus du 17 mars 1999: Objectifs, indications et modalités du sevrage du patient alcoolodépendant. http://www.has-sante.fr/portail/upload/docs/application/pdf/alccol2.pdf (Accessed 01/09/15).
8. Rolland B, Laprevote V, Geoffroy PA, Guardia D, Schwan R, Cottencin O. Abstinence dans l'alcoolodépendance: Approche critique et actualisée des recommandations nationales de 2001. Presse Med 2013;42:19-25.
9. Cottencin O, Harbonnier J, Guardia D, Rolland B, Danel T. The system of medical treatment for addiction in france. Int J Ment Health 2014;43:19-26.
10. Rolland B, Bordet R, Cottencin O. Alcohol-dependence: The current French craze for baclofen. Addiction 2012;107:848-849.
11. Société Française d'Alcoologie. Alcohol misuse: screening, diagnosis and treatment. 2015. http://www.sfalcoologie.asso.fr/download/SFA-GPR-AlcoholMisuse.pdf?PHPSESSID=9da9bde13d18fec259c6001837efa055 (Accessed 01/09/15).
12. Société Française d'Alcoologie. Mésusage de l'alcool: Dépistage, diagnostic et traitement. Recommandations de bonne pratique. Alcoologie et Addictologie 2015;37:5. http://www.sfalcoologie.asso.fr/download/RBP2014-SFA-Mesusage-AA.pdf (Accessed 01/09/15).
13. Rolland B, Mann K, Paille F, Aubin H-J. The new French guidelines on alcohol misuse: An initiative for strengthening cross-European interplay. Addiction 2015;110:1362-1363.
14. Haute Autorité de Santé. Practice Guidelines: "Clinical practice guidelines" method. 2011. http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-07/guideline_by_cpg_method_-_quick_methodology_guide_-_4_pages.pdf (Accessed 01/09/15).
15. Haute Autorité de Santé. About HAS. http://www.has-sante.fr/portail/jcms/r_1455134/fr/about-has. (Accessed 01/09/15).
16. Gastfriend DR, Garbutt JC, Pettinati HM, Forman RF. Reduction in heavy drinking as a treatment outcome in alcohol dependence. J Subst Abuse Treat 2007;33:71-80.
17. Luquiens A, Aubin H-J. Patient preferences and perspectives regarding reducing alcohol consumption: Role of nalmefene. Patient Prefer Adherence 2014;8:1347-1352.
18. Vaillant GE. A 60-year follow-up of alcoholic men. Addiction 2003;98:1043-1051.
19. Gual A, Bravo F, Lligoña A, Colom J. Treatment for alcohol dependence in Catalonia: Health outcomes and stability of drinking patterns over 20 years in 850 patients. Alcohol Alcohol 2009;44:409-415.
20. Subbaraman MS, Witbrodt J. Differences between abstinent and non-abstinent individuals in recovery from alcohol use disorders. Addict Behav 2014;39:1730-1735.
21. Al-Otaiba Z, Worden BL, McCrady BS, Epstein EE. Accounting for self-selected drinking goals in the assessment of treatment outcome. Psychol Addict Behav 2008;22:439-443.
22. Adamson SJ, Heather N, Morton V, Raistrick D. Initial preference for drinking goal in the treatment of alcohol problems: II. Treatment outcomes. Alcohol Alcohol 2010;45:136-142.
23. World Health Organization. Empowering patients. 2012. http://www.euro.who.int/en/what-we-do/health-topics/noncommunicable-diseases/sections/news/2012/4/empowering-patients (Accessed 01/09/15).
24. Hall W, Zador D. The alcohol withdrawal syndrome. Lancet 1997;349:1897-1900.
25. Maldonado JR, Sher Y, Ashouri JF, et al. The «Prediction of Alcohol Withdrawal Severity Scale» (PAWSS): Systematic literature review and pilot study of a new scale for the prediction of complicated alcohol withdrawal syndrome. Alcohol 2014;48:375-390.
26. Schuckit MA. Alcohol-use disorders. Lancet 2009;373:492-501.
27. Hayashida M, Alterman AI, McLellan AT, et al. Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome. N Engl J Med 1989;320:358-365.
28. Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev 2010; (3):CD005063.
29. Rehm J, Allamani A, Aubin HJ, et al. People with alcohol use disorders in specialized care in eight different European countries. Alcohol Alcohol 2015;50:310-318.
30. Daeppen JB, Gache P, Landry U, et al. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: A randomized treatment trial. Arch Intern Med 2002;162:1117-1121.
31. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: The revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989;84:1353-1357.
32. Cushman P, Forbes R, Lerner W, Stewart M. Alcohol withdrawal syndromes: Clinical management with lofexidine. Alcohol Clin Exp Res 1985;9:103-108.
33. Sonne J, Andreasen PB, Loft S, Døssing M, Andreasen F. Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. Hepatol 1990;11:951-956.
34. Latt N, Dore G. Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders. Intern Med J 2014;44:911-915.
35. US Department of Helath & Human Services, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism. Helping patients who drink too much. A clinican's guide. 2005. http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/guide.pdf (Accessed 01/09/15).
36. Furtwaengler NAFF, de Visser RO. Lack of international consensus in low-risk drinking guidelines. Drug Alcohol Rev 2013;32:11-18.
37. Bouza C, Angeles M, Magro A, Muñoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction 2004;99:811-828.
38. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful? Addiction 2013;108:275-293.
39. Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis. JAMA 2014;311:1889-1900.
40. Jørgensen CH, Pedersen B, Tønnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res 2011;35:1749-1758.
41. Skinner MD, Lahmek P, Pham H, Aubin H-J. Disulfiram efficacy in the treatment of alcohol dependence: A meta-analysis. PLoS ONE 2014;9:e87366.
42. Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 1999;20:427-435.
43. Dupouy J, Fournier JP, Jouanjus E, et al. Baclofen for alcohol dependence in France: Incidence of treated patients and prescription patterns-A cohort study. Eur Neuropsychopharmacol 2014;24:192-199.
44. Rolland B, Paille F, Fleury B, Cottencin O, Benyamina A, Aubin HJ. Off-label baclofen prescribing practices among French alcohol specialists: Results of a National Online Survey. PLoS ONE 2014;9:e98062.
45. Müller CA, Geisel O, Pelz P, et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): A randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2015;25:1167-1177.
46. BACLOVILLE study (NCT01604330). Baclofen for the Treatment of Alcohol Drinkers - Full Text View - ClinicalTrials.gov. 2012. http://clinicaltrials.gov/ct2/show/NCT01604330 (Accessed 01/09/15).
47. ALPADIR study (NCT01738282). Efficacy and Safety of Baclofen for Maintenance of Abstinence in Alcohol Dependent Patients - Full Text View - ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT01738282 (Accessed 01/09/15).
48. Auffret M, Rolland B, Deheul S, et al. Severe tinnitus induced by off-label baclofen. Ann Pharmacother 2014;48:656-659.
49. Rigal L, Legay HL, Alexandre-Dubroeucq C, Pinot J, Le JC, Jaury P. Tolerability of high-dose baclofen in the treatment of patients with alcohol disorders: A retrospective study. Alcohol Alcohol 2015;50:551-557.
50. Rolland B, Labreuche J, Duhamel A, et al. Baclofen for alcohol dependence: Relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol 2015; 25:1631-1636.
51. Rolland B, Deheul S, Danel T, Bordet R, Cottencin O. A case of de novo seizures following a probable interaction of high-dose baclofen with alcohol. Alcohol Alcohol 2012;47:577-580.
52. Geoffroy PA, Auffret M, Deheul S, Bordet R, Cottencin O, Rolland B. Baclofen-induced manic symptoms: Case report and systematic review. Psychosomatics 2014;55:326-332.
53. Rolland B, Jaillette E, Carton L, et al. Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder. J Clin Psychopharmacol 2014;34:153-156.
54. Agence Française du Médicament et des produits de santé. Recommandation temporaire d'utilisation (RTU) pour le baclofène - Point d'information 2014. http://ansm.sante.fr/S-informer/Actualite/Une-recommandation-temporaire-d-utilisation-RTU-est-accordee-pour-le-baclofene-Point-d-information (Accessed 01/09/15).
55. Rehm J, Greenfield TK, Rogers JD. Average volume of alcohol consumption, patterns of drinking, and all-cause mortality: Results from the US National Alcohol Survey. Am J Epidemiol 2001;153:64-71.
56. Rehm J, Roerecke M. Reduction of drinking in problem drinkers and all-cause mortality. Alcohol Alcohol 2013;48:509-513.
57. Michie S, Whittington C, Hamoudi Z, Zarnani F, Tober G, West R. Identification of behaviour change techniques to reduce excessive alcohol consumption. Addiction 2012;107:1431-1440.
58. Mann K, Bladström A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: A randomized controlled study of as-needed nalmefene. Biol Psychiatry 2013;73:706-713.
59. Rösner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: Evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 2008;22:11-23.
60. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol 1994;8:461-475.
61. Wikner BN, Stiller C-O, Bergman U, Asker C, Källén B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: Neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:1203-1210.
62. Kuperman S, Chan G, Kramer JR, et al. Relationship of age of first drink to child behavioral problems and family psychopathology. Alcohol Clin Exp Res 2005;29:1869-1876.
63. Grant JD, Scherrer JF, Lynskey MT, et al. Adolescent alcohol use is a risk factor for adult alcohol and drug dependence: Evidence from a twin design. Psychol Med 2006;36:109-118.
64. Salzman C, Shader RI, Greenblatt DJ, Harmatz JS. Long v short half-life benzodiazepines in the elderly. Kinetics and clinical effects of diazepam and oxazepam. Arch Gen Psychiatry 1983;40:293-297.
65. Wilkinson GR. The effects of liver disease and aging on the disposition of diazepam, chlordiazepoxide, oxazepam and lorazepam in man. Acta Psychiatr Scand 1978;274:56-74.
66. Ballokova A, Peel NM, Fialova D, Scott IA, Gray LC, Hubbard RE. Use of benzodiazepines and association with falls in older people admitted to hospital: A prospective cohort study. Drugs Aging 2014;31:299-310.
67. Blazer DG, Wu L-T. The epidemiology of at-risk and binge drinking among middle-aged and elderly community adults: National Survey on Drug Use and Health. Am J Psychiatry 2009;166:1162-1169.
68. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study. Lancet 2007;370:1915-1922.
69. DiMartini A, Dew MA, Day N, et al. Trajectories of alcohol consumption following liver transplantation. Am J Transplant 2010;10:2305-2312.
70. Lucey MR. Liver transplantation in patients with alcoholic liver disease. Liver Transplant 2011;17:751-759.
71. Dumortier J, Dharancy S, Cannesson A, et al. Recurrent alcoholic cirrhosis in severe alcoholic relapse after liver transplantation: A frequent and serious complication. Am J Gastroenterol 2015;110:1160-1166.
72. Sullivan EV, Rosenbloom MJ, Lim KO, Pfefferbaum A. Longitudinal changes in cognition, gait, and balance in abstinent and relapsed alcoholic men: Relationships to changes in brain structure. Neuropsychology 2000;14:178-188.
73. Davidson KM. Diagnosis of depression in alcohol dependence: Changes in prevalence with drinking status. Br J Psychiatry 1995;166:199-204.
74. Liappas J, Paparrigopoulos T, Tzavellas E, Christodoulou G. Impact of alcohol detoxification on anxiety and depressive symptoms. Drug Alcohol Depend 2002;68:215-220.
75. Torrens M, Fonseca F, Mateu G, Farré M. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend 2005;78:1-22.
76. Joseph AM, Willenbring ML, Nugent SM, Nelson DB. A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. J Stud Alcohol 2004;65:681-691.
77. National Institute for Health and Clinical Excellence. Alcohol use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. 2011. http://www.nice.org.uk/nicemedia/live/13337/53191/53191.pdf (Accessed 01/09/15).
78. Australian Government. Department of Health and Ageing. Guidelines for the Treatment of Alcohol Problems. 2009. http://www.health.gov.au/internet/ministers/publishing.nsf/Content/76AE6384CE9A3830CA2576BF003073F8/$File/DEZEM_Alcohol%20Guide_FA.pdf (Accessed 01/09/15).
79. Peppers MP. Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy 1996;16:49-57.
80. Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997;278:144-151.
81. Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 1981;6:89-105.
82. Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev 2010; (2):CD006266.
83. Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: A self-case report of a physician. Alcohol Alcohol 2005;40:147-150.
84. Gache P. [Baclofen: The new miracle cure for alcoholism?] Le baclofène sera-t-il le nouveau médicament miracle de l'alcoolisme? Rev Med Suisse 2011;7:1458-1461.
85. Dom G. Why Belgian alcohol patients are treated differently than their French counterparts. Acta Clin Belg 2012;67:315-316.
86. Pastor A, Jones DML, Currie J. High-dose baclofen for treatment-resistant alcohol dependence. J Clin Psychopharmacol 2012;32:266-268.
87. Mirijello A, Caputo F, Vassallo G, et al. GABAB agonists for the treatment of Alcohol Use Disorder. Curr Pharm Des 2015;21:3367-3372.
88. Heather N, Adamson SJ, Raistrick D, Slegg GP. Initial preference for drinking goal in the treatment of alcohol problems: I. Baseline differences between abstinence and non-abstinence groups. Alcohol Alcohol 2010;45:128-135.
89. Gual A, He Y, Torup L, van den Brink W, Mann K, ESENSE 2 Study Group. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 2013;23:1432.
90. van den Brink W, Aubin H-J, Bladström A, Torup L, Gual A, Mann K. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: Results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol 2013;48:570-578.
91. Aubin HJ, Reimer J, Nutt DJ, et al. Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients. Eur Addict Res 2015;21:160-168.
92. François C, Rahhali N, Chalem Y, Sørensen P, Luquiens A, Aubin HJ. The effects of as-needed nalmefene on patient-reported outcomes and quality of life in relation to a reduction in alcohol consumption in alcohol-dependent patients. PLoS ONE 2015;10:e0129289.
93. Mann KF. Why should we need a European Federation of Addiction Societies? Addiction 2008;103:6-8.